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Background: Colorectal carcinoma is a common cause of cancer. Adjuvant treatments include: 5-fluorouracil
administered together with folinic acid, or more recently, oral fluoropyrimidines such as capecitabine, in combination
with oxaliplatin or irinotecan. Metastatic colorectal cancer patients can benefit from other additional treatments such
as cetuximab or bevacizumab.
Methods: Using cell culture techniques, we isolated clonal populations from primary cultures of ascitic effusion
derived from a colon cancer patient and after several passages an established cell line, HGUE-C-1, was obtained.
Genetic analysis of HGUE-C-1 cells was performed by PCR of selected exons and sequencing. Cell proliferation studies
were performed by MTT assays and cell cycle analyses were performed by flow cytometry. Retinoblastoma
activity was measured by luciferase assays and proteins levels and activity were analysed by Western blot or
immunohistochemistry.
Results: We have established a new cell line from ascitic efussion of a colon cancer patient who did not respond to
5-fluorouracil or irinotecan. HGUE-C-1 cells did not show microsatellite instability and did not harbour mutations in
KRAS, BRAF, PI3KCA or TP53. However, these cells showed loss of heterozygosity affecting Adenomatous Polyposis Coli
and nuclear staining of β-catenin protein. The HGUE-C-1 cell line was sensitive to erlotinib, gefitinib, NVP-BEZ235,
rapamycin and trichostatin, among other drugs, but partially resistant to heat shock protein inhibitors and
highly resistant to AZD-6244 and oxaliplatin, even though the patient from which this cell line was derived
had not been exposed to these drugs. Molecular characterization of this cell line revealed low expression levels and
activity of Retinoblastoma protein and elevated basal levels of Erk1/2 activity and p70S6K expression and activity,
which may be related to chemoresistance mechanisms.
Conclusions: HGUE-C-1 represents a novel and peculiar colon carcinoma model to study chemoresistance to
chemotherapeutic agents and to novel anti-neoplasic drugs that interrupt signalling pathways such as the
APC/βcatenin, Ras/Raf/Mek/Erk, PI3K/mTOR/p70S6K pathways as well as histone regulation mechanisms.
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Colorectal cancer (CRC) is the third most common type
of cancer, constituting approximately 9.4% of all cancers
diagnosed, and the third leading cause of cancer death.
Approximately, 25% of patients diagnosed of colorec-
tal cancer have already metastatic spread, and 25% of
initially localized disease will develop metastases [1]. The
recommended strategy for locally advanced colon cancer
consists of preoperative combined chemo and radiother-
apy, followed by surgery and then by adjuvant chemother-
apy, to reduce both the local recurrence and the possibility
of distant relapse [2]. Adjuvant chemotherapy in stage III
colon cancer is fully justified. The combination of 5-
fluorouracil (5-FU) and folinic acid (leucovorin), which
enhances 5-FU effects by inhibiting thymilydate synthase,
administered for six months, or oral fluoropyrimidines
such as the 5-FU prodrugs capecitabine [3] or tegafur [4],
are able to reduce the risk of death by 30%, assuming an
absolute increase of 10-13% in terms of survival. Further
combination of oxaliplatin either to the regimen of 5-FU
and folinic acid or to capecitabine increased survival in
this group of patients [5-7]. Indication and treatment of
stage II disease is controversial and depends on clinical
and histological risk factors [8]. Considering advanced dis-
ease, first-line chemotherapy including the combination of
folinic acid with continuous infusion of 5-FU, along with
oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are reason-
able choices, with comparable effectiveness in terms of
objective responses and survival [9]. Capecitabine combi-
nations have shown similar efficacy to continuous infusion
of 5-FU combinations [10-13]. Bevacizumab, a humanized
monoclonal antibody against vascular endothelial growth
factor (VEGF), and cetuximab, a monoclonal antibody di-
rected against the extracellular domain of the epidermal
growth factor receptor (EGFR), have demonstrated an
additive effect on chemotherapy, therefore broadening the
options for treatments of patients in first and consecutive
lines [14,15]. However, anti-EGFR therapy is only recom-
mended in KRAS/BRAF wild type patients.
Recently, we have established primary cultures ob-
tained from patients with CRC cancer. The novel colon
cancer cell line HGUE-C-1 was obtained from ascitic efus-
sion of a 76-year old man with colon cancer. The patient
was initially admitted at the hospital, in November 2003.
A complete colonoscopy was performed, showing a mass
eight centimetres long, starting eighteen centimetres far
from the anal verge. The biopsy confirmed diagnosis of
colon adenocarcinoma. R0 down anterior resection was
performed, resulting in a moderately differentiated colon
adenocarcinoma affecting serosa, with two out of eleven
metastatic lymph nodes (GII pT3 N1b). After postopera-
tive evaluation consisting of thorax-abdomen-pelvic CT
scan which showed no evidence of residual disease, and
carcinoembrionary antigen (CEA) value in the normalrange, adjuvant chemotherapy with 5-FU and folinic acid
was administered for six months. After completing adju-
vant chemotherapy, there was no suspect or evidence of
relapse by imaging tests and blood analysis. The pa-
tient entered at that time onto a scheduled follow-up
programme. Two years later, the patient was admitted
into the hospital due to an increase in the abdominal per-
imeter. Thorax-abdomen-pelvic CT scan revealed massive
ascites. The cytology performed on ascitic fluid obtained
after diagnostic paracentesis confirmed colon adenocar-
cinoma origin of the ascites. Palliative chemotherapy was
then started with capecitabine and irinotecan. After a sec-
ond cycle of chemotherapy, the patient was admitted into
the hospital due to grade III chemotherapy-induced diar-
rhea. During admission, two parecenteses of malignant
haematic ascites with 72 hours interval were performed
(5,000 and 5,400 ml). The patient received a third cycle of
treatment on an outpatient basis with 25% reduction in
doses of capecitabine and irinotecan. Seven days after be-
ginning of the third cycle, the patient was again admitted
into the hospital due to grade III diarrhea associated to
renal failure. The patient showed no response to medical
procedures, and considering the global prognosis, exclu-
sive symptomatic treatment was decided. Patient died
eight days after final admission.
The new HGUE-C-1 cell line constitutes an interesting
model of study from several points of view. Initially, we
determined whether HGUE-C-1 cells presented the micro-
satellite instability (MSI) phenotype, already known to be
related to colorectal carcinogenesis in about 15% of all
CRC [16]. Interestingly, HGUE-C-1 cells did not show
MSI phenotype. HGUE-C-1 cells were also analysed for
mutations in KRAS, BRAF, PIK3CA and TP53 genes,
which are quite commonly mutated in colon carcinoma
and have been related to colon carcinogenesis [17-19].
Further analysis with the dinucleotide polymorphic repeat
marker D5S346 showed loss of heterozygosity affecting
the Adenomatous Polyposis Coli (APC) containing region
in chromosome five and nuclear staining of β-catenin
protein, suggesting that the APC signalling pathway was
modified in HGUE-C-1 cells.
HGUE-C-1 cells are also interesting as an experimental
model for the study of chemoresistance in patients with
colon cancer. In this sense, HGUE-C-1 cells show resist-
ance to 5-FU and irinotecan. This cell line constitutes a
better physiological model for chemoresistance studies in
comparison with other cell lines that become resistant
in vitro by selective pressure after treatment with increas-
ing concentrations of specific drugs.
HGUE-C-1 represents an established cell line derived
from primary cultures of a biological sample obtained
from a patient, in the context of a general project aimed
to the development of predictive tests with a panel of dif-
ferent alternative treatments. In this context, a complete
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Interestingly, the HGUE-C-1 cell line showed chemosensi-
tivity to EGFR inhibitors erlotinib, gefitinib, the dual
PI3K/mTOR inhibitor NVP-BEZ235, the mTOR inhibitor
rapamycin, the histone deacetylase inhibitor trichostatin
(TSA) among other drugs, being partially resistant to the
heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG), and totally resistant
to the Mek inhibitor AZD-6244 (Selumetinib) and to the
chemotherapeutic agent oxaliplatin, despite that the patient
was not treated with such drugs. The putative molecular
mechanisms involved in HGUE-C-1 carcinogenesis, and
drug chemosensitivity or chemoresistance will be dis-
cussed herein.
Methods
Cell culture
The human colorectal cancer cell lines HT-29, SW620,
SW480, HCT-15 and HCT-116 cells were obtained from the
Instituto Municipal de Investigaciones Médicas de Barcelona
(Spain), HT-29, SW480, HCT-15, HGUE-C-1, SW620 and
HCT-116 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Labclinics SA, Barcelona, Spain)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Labclinics), 50 U/mL of penicillin and 50 mg/mL
streptomycin (Labclinics) and incubated at 37°C in a humidi-
fied 5%CO2/air atmosphere.
Reagents
Gefitinib, erlotinib, sorafenib, 17-AAG, NVP-BEZ235 and
AZD-6244 were obtained from ChemieTek (Indianapolis,
IN, USA). Rapamycin, tricostatin (TSA), propidium iodide
and 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). RNase A was obtained from Serva
(Heidelberg, Germany).
Cell proliferation assays
Cell proliferation was assessed using the MTT assay
based on the activity of the mitochondrial enzyme suc-
cinate dehydrogenase. Colorectal carcinoma cells were
seeded in 96-well plates at a density of 2,500 cells per well
and incubated at 37°C with 5% CO2. Increasing doses of
the indicated drugs were added, with DMSO as non-
treated control. The dose range for each drug was selected
taking in consideration the maximal and the minimal con-
centration of the drug in patient´s plasma and/or previous
MTT assays dose response studies in our panel of colon
cancer cell lines. The culture was continued for 72 hours
and at the end of the treatment, 30 μl of MTT solution
(5 mg/ml in PBS) were added into each well, followed by
incubation at 37°C for three hours. The culture medium
containing MTT was aspirated and the formazan crystals
formed were then solubilized with 200 μl DMSO for30 minutes. Absorbance was measured at wavelength
570 nm in a microplate reader (Anthos 2001 Labtec
Instruments GmbH, Wals, Austria), and the percentage
of proliferation of HGUE-C-1 and HT-29 cells was deter-
mined for each concentration of the indicated drug. Both
treatment and control groups were performed in 6 repli-
cate wells and the experiment was repeated at least three
times to ensure the data reproducibility.
Cell cycle analysis
Cells were cultured in T25 flasks and treated with the
different drugs at the indicated concentration with
DMSO as non-treated control. At the end of the treat-
ment, both floating and adherent cells were collected,
combined, washed with PBS, and fixed with 500 μl of
chilled 70% ethanol in PBS at −20°C. Following fixation,
cells were pelleted and resuspended in 500 μl of PBS
containing 0.5% Triton X-100, 25 μg/ml RNase A and
25 × 10−3 μg/ml propidium iodide. After 30 minutes at
room temperature in the dark, cell cycle distribution was
determined with an Epics XL flow cytometer (Beckman
Coulter Co., Miami, FL). When the fluorescence is less
than the fluorescence peak corresponding to that of the
G0/G1-phase, cells are considered to be apoptotic (sub-G1).
Western blot analysis
Cells were plated for different times in serum-starved
conditions, lysed in NP-40 lysis buffer (50 mM Tris–HCl
pH 7.4, 1% NP-40, 150 mM NaCl, 5 mM EDTA, 50 mM
NaF, 30 mM Na4P2O7, 1 mM Na3VO4,) with a protease
inhibitor cocktail (Sigma-Aldrich) for 30 min on ice. After
centrifugation at 15,000 x g for 5 minutes at 4°C, the su-
pernatants were collected and the protein concentration
of the cell lysates was determined by the Bradford method
(Bio-Rad, Richmond, CA). Total protein content (60–80
μg) from each lysate was electrophoresed on 10% poly-
acrylamide gels in the presence of sodiumdodecyl sulfate
(SDS) and transferred onto nitrocellulose membranes.
Nonspecific sites were blocked incubating for 1 hour at
room temperature with 5% non-fat dry milk. Membranes
were then incubated overnight with the indicated pri-
mary antibodies. EGFR and HER3 antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); phospho-ERK1/2, ERK1/2, phospho-p70S6K,
p70S6K, phospho-RPS6 and RPS6 antibodies were pur-
chased from Cell Signaling Technologies (Danvers,
MA); Retinoblastoma antibody was purchased from BD
Biosciences (San Jose, CA); actin antibody was purchased
from Sigma-Aldrich. The primary antibodies were incu-
bated with secondary antibodies linked to horseradish per-
oxidase (GE Healthcare, Buckinghamshire, UK). Specific
proteins were visualized by enhanced chemiluminescence
detection using the ECL system (GE Healthcare), accord-
ing to the manufacturer’s instructions.
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HT-29 and HGUE-C-1 cells were seeded in 24-well cul-
ture plates (180,000 and 150,000 cells/well, respectively).
When cells reached 40–60% confluence (24 hr), they
were transiently transfected with 0.8 μg of pRb-TA-Luc
or pE2F-TA-Luc responsive luciferase reporter plasmid
(Clontech, Mountain View, CA), using Lipofectamine2000
reagent (Invitrogen, Carlsbad, CA, USA) in a DNA trans-
fection agent ratio of 1:3. The pTa-Luc vector lacking the
response element was used as negative control. Six hours
after transfection, culture medium was replaced by fresh
medium and cells were kept under normal growth condi-
tion in DMEM with 10% foetal serum for 24 hours prior
to lysis and luciferase detection. All transfections were
performed as co-transfections using a Renilla luciferase
expression plasmid (Promega Corporation, Madison, WI)
to establish an internal control for transfection efficiency.
The transfected cells were washed once with PBS and
lysed using 100 μl Passive Lysis Buffer (Promega). Firefly
and Renilla luciferase activities were determined using the
Dual-Luciferase Reporter Assay System (Promega) accord-
ing to the manufacturer’s instructions, using for detection of
the chemiluminescent signal, a luminometer from Berthold
(Montreal Biotech, Kirkland, QC). Promoter activities of
the RB and E2F reporter plasmids were expressed using
the arbitrary units “RLU” (relative luciferase units).
HGUE-C-1 genetic analysis
DNA from different passages of HGUE-C-1 cells was
isolated using the DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA). HGUE-C-1 cells were screened for MSI status
by multiplex PCR using the pentaplex set of monomorphic
markers (BAT 26, BAT 25, NR21, NR24 and NR27). Mu-
tations in BRAF (V600E) and KRAS (codon 12/13) were
identified by direct sequencing. Primer sequences were
BRAF:F-TGCTTGCTCTGATAGGAAAATGA, BRAF:R-
TGGATCCAGACAACTGTTCAAA, KRAS.F-GCCTGC
TGAAAATGACTGAA and KRAS:R- AGAATGGTCC
TGCACCAGTAA. PCR products were purified using a
QIAquick PCR purification kit (Qiagen) and directly
sequenced on an ABI PRISM 3100 sequencer (Applied
Biosystems, Foster City, CA). Presence of PIK3CA muta-
tions in exons 9 and 20 were determined by direct sequen-
cing after a nested PCR reaction. Amplicons were purified
and subjected to direct sequencing using exosap-kit (USB
Corporation) and sequenced using the primers PI542-5IF
and PI542-5IR for exon 9 and PI1047IF and PI1047IR for
exon 20 with BigDye Terminator Sequencing Kit and ABI
PRISM 3100 sequencer (Applied Biosystems). TP53 gene
mutations were determined on genomic DNA from two
different culture passages, p3 and p30, of HGUE-C-1 cells.
Mutations in exons 4–11 were analysed by PCR amplifica-
tion and direct sequencing of the coding sequence and
exon-intron boundaries. The PCR amplified productswere purified and sequenced. Three dinucleotide poly-
morphic repeat markers (D2S123, D5S346 and D17S250)
were amplified by PCR using fluorescent labelled primers
and analysed by capillary electrophoresis in an ABI PRISM
3100 sequencer (Applied Biosystems). The size of the
markers was compared at two different cell culture pas-
sages p3 and p45.
Immunohistochemistry
Three-micrometre sections were cut from paraffin-
embeded tumour specimens and the slides were pre-
treated in a PT link from Dako (Glostrup, Denmark)
and incubated with antibodies against β-catenin. Signal
amplification and development were carried out with
EnVision Flex kit (Dako), according to the manufac-
turer’s instructions.
Ethics statement
Ascitic efussion (from where HGUE-C-1 cells were de-
rived) of a patient with colon cancer was obtained ac-
cording to institutional guidelines with the approval of
the “Comité Etico y de Investigación Clínica” (Clinical
Research and Ethics Committee) Review Board, Hospital
General Universitario de Elche, Elche, Spain. This ethics
committee waived the need for informed consent for this
particular kind of human samples.
Results
Phenotypical characterization of the HGUE-C-1 cell line
Initially, the DNAs obtained from early passages of
HGUE-C-1 cells (passage 3) and from the individual
clones of HGUE-C-1 (A,B,E, F,G and H) isolated after pas-
sage 15 of the original HGUE-C-1 culture, were analysed
for microsatellite instability (MSI) status with probes
for the pentaplex set of monomorphic markers (NR21,
BAT25, BAT26, NR22 and NR24). Results in Figure 1
demonstrate that the parental HGUE-C-1 cells as well as
the HGUE-C-1 clonal populations A, B, E, F, G and H do
not present MSI phenotype. Next, DNA from early and
late passages of HGUE-C-1 cells was evaluated for pres-
ence of mutations on TP53, BRAF (V600E), KRAS (codons
12 and 13) and PIK3CA (codons 9 and 20). Results in
Table 1 indicate that different passages of the HGUE-C-1
cell line do not harbour mutations in any of the analysed
genes.
Western blot analysis of different proteins involved in
signal transduction pathways were performed in order to
find differences between HGUE-C-1 cells and others
well characterized colon carcinoma cell lines, such as
HT-29. As shown in Figure 2A and B, Retinoblastoma
(Rb) protein levels are lower in HGUE-C-1 cells when
compared with HT-29, SW620, SW480 and HCT-15
cells. Rb activity, determined by transient transfection
assays with Rb and E2F reporter genes, is also lower in
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Figure 1 Phenotypical characterization of the HGUE-C-1 cells. Probes for the pentaplex set of monomorphic markers were used to determine
MSI on DNA samples from passage 3 of HGUE-C1 cells and from passage 15 of clones A, B, E, F, G and H.
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Table 1 DNA from early and late passages of HGUE-C-1 cells
was tested for mutational status of TP53, BRAF (V600E),
KRAS (codons 12 and 13) and PIK3CA (exons 9 and 20)
Passage 3 Passage 36
TP53 wt wt
BRAF wt wt
KRAS wt wt
PIK3CA wt wt
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cells show high expression levels of p70S6K (RPS6KB1)
protein under serum-starved conditions, as compared with
HT-29, SW620, SW480 and HCT-15 cells (Figure 3A). In
addition, p70S6K is constitutively active in HGUE-C-1
cells, as demonstrated by high levels of phosphorylated
p70S6K (Figure 3A) and by the presence of phosphorylated
RPS6, its downstream target (Figure 3B). Likewise, Erk1
and Erk2 appear constitutively active (Figure 3C) under
serum-starved conditions in HGUE-C-1 cells, in contrast
to the activity level of these proteins observed in HT-29,
SW620, SW480 and HCT-15 cells. However, when Akt,
RSK and other key protein were analysed no significant
differences in activity and levels were observed between
both cell lines (data not shown). Finally, protein levels of
members of the HER receptor family such as EGFR and
HER3 were analysed in HGUE-C-1 and others colon can-
cer cell lines. HGUE-C-1 cells do not express HER3 pro-
tein, whereas HT-29, SW620, SW480 and HCT-15 cells
express this receptor (Figure 3D).
To determine whether APC gene was affected in
HGUE-C-1 cells, the dinucleotide polymorphic repeat
marker D5S346 was studied in DNA samples obtained
from two different passages of HGUE-C-1 cells, as well
as in DNA obtained from non- tumour cells from the
same patient. HGUE-C-1 cells showed loss of heterozy-
gosity in APC related region of chromosome 5 (data not
shown).
Pharmacological profile of HGUE-C-1 cells
One of the main objectives of the HGUE-C-1 cell culture
generation was to develop predictive tests of chemoresis-
tance in primary cultures obtained from biological sam-
ples of patients with colorectal cancer. HGUE-C-1 cells
were treated with different drugs in order to test their sen-
sitivity either when they were set in culture for the first
time, or when they had been cultured for several passages,
in order to determine its pharmacological profile. The
results show that HGUE-C-1 cells are resistant to 5-FU
and irinotecan compared to other colorectal cancer cell
lines, as seen in Figures 4A and B. HGUE-C-1 cells also
show resistance to cetuximab (Figure 5A), despite the
patient was not treated with this EGFR antibody. Inter-
estingly, HGUE-C-1 cells show sensitivity to erlotiniband gefitinib, inhibitors of the EGFR tyrosine quinase
activity (Figure 5B). HGUE-C-1 cells are also sensitive to
the m-TOR inhibitor rapamycin, the dual PI3K and m-TOR
inhibitor NVP-BEZ235, the BRAF inhibitor sorafenib and
the histone deacetylase inhibitor TSA (Figure 6A-D).
Interestingly, HGUE-C-1 cells show partial response to
the Hsp90 inhibitor 17-AAG (Figure 7A) and resistance to
the MEK inhibitor AZD-6244 (selumetinib) (Figure 7B)
and to oxaliplatin (Figure 7C), as compared to other colon
carcinoma cell lines, despite the patient was not treated
with these drugs.
Drugs effects on HGUE-C-1 cell cycle
Taking in consideration that HGUE-C-1 cells show low
levels of Rb protein expression, compromising the regu-
lation of cell cycle checkpoints and, since most of the
drugs tested play a role on cell cycle regulation, we ana-
lysed the effects of the different treatments on the distri-
bution of DNA content of the different phases of the cell
cycle by flow cytometry in HGUE-C-1 and HT-29 cells.
Results in Figure 8(A-H) show that NVP-BEZ235, AZD-
6244 and sorafenib (Figure 8A, E and G, respectively) are
able to induce a G1 phase arrest in HT-29 cells, whereas
17-AGG induces a G2/M arrest, and subsequently accu-
mulation in the SubG1 phase, indicative of apoptotic cell
death (Figure 8C). However, HGUE-C-1 cells respond in a
completely different manner after the same drug treatments.
NVP-BEZ235 and sorafenib induce cell death without the
G1 arrest observed in HT-29 cells (Figure 8B and H). Simi-
larly but to a lesser extent, 17-AAG induces an increment
in the SubG1 phase of the cell cycle (Figure 8D) in HGUE-
C-1 cells, whereas this drug induces a G2/M arrest in
HT-29 cells (Figure 8C). Almost no variation on cell cycle
distribution was observed in HGUE-C-1 cells after AZD-
6244, apart from a small and no significant increase in
apoptotic cells without any evidence of cell cycle blockade
(Figure 8F). Taking together, these results indicate that
after treatment with these drugs, HGUE-C-1 cells undergo
apoptosis with no previous arrest of the cell cycle. Similar
commitment to apoptosis in HGUE-C-1 cells was ob-
served after TSA treatment (data not shown).
HGUE-C-1 identity control
In order to identify putative molecular or genetic changes
associated to cell culture and to validate the pharmaco-
logical profile shown in Figures 4, 5 and 6, different char-
acteristics of HGUE-C-1 cells have been analysed in the
initial primary cell cultures and in different cell passages.
As a cross contamination control, we analysed the poly-
morphic microsatellite markers D2S123, D5S346 (previ-
ously mentioned) and D17S25in DNA samples obtained
from two different passages. Both passages show the same
pattern for the three MSI markers analysed, confirming a
very high probability of identity (data not shown). Since
Figure 2 Retinoblastoma (Rb) protein expression and activity. HGUE-C-1 and HT-29, SW620, SW480 and HCT-15 colorectal carcinoma cells
were grown, lysed and subjected to Western blot analyses to detect levels of Rb or β-actin, using specific antibodies. β-actin was used as a
loading control (2A). Densitometric values of Rb bands were normalized to β-actin bands and represented as the average of at least three
experiments. Error bars are the S.E.M. (2B). Retinoblastoma activity was determined on HT-29 and HGUE-C-1 cell lines by transient transfection assays
with Rb and E2F reporter genes and represented as the average of at least four experiments. Error bars are the S.E.M. (2C).
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with colorectal cancer and not from the primary tumour
excised two years before, and also because the patient had
been heavily exposed to chemotherapy, we wanted to
know the degree of heterogeneity inside the putative
tumour cell population presented in the HGUE-C-1 cells.
We isolated clonal cell populations from the HGUE-C-1
primary culture after 15 passages in culture (non-tumour
cells have already undergone senescence at that point). We
then analysed isolated clonal populations of HGUE-C-1
cells to determine MSI status (results shown in Figure 1)
and their response to different drug treatments. We chose
TSA because these cells are sensitive to this drug (Figure 6)
and 5-FU because these cells have already been exposed to
this chemotherapeutic agent. In Figure 9A we observedthat the response to TSA treatment is quite similar in all
clonal populations of HGUE-C-1 cells. However, different
degree of resistance to 5-FU can be observed among the
HGUE-C-1 clonal populations (Figure 9B).
Finally, we wanted to determine whether the results that
we obtained testing the sensitivity to different drugs per-
formed in HGUE-C-1 cells at the beginning of the culture
correlate with the pharmacological profile of the cells after
a well-established culture. We found a good correlation
between the pharmacological profiles in both cases (data
not shown). In addition and since HGUE-C-1 cells show
cross resistance to different treatments, we studied the
status of MDR1 and MRP1 protein levels and activity. We
found that HGUE-C-1 cells do not show MDR1 and
MRP1 expression and more importantly, they did not
BA
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Figure 3 Expression and activity of signalling molecules. HGUE-C1, HT-29, SW620, SW480 and HCT-15 cells were grown, serum-starved for 48
hours, lysed and subjected to Western blot analyses using antibodies against p70S6K and phosphorylated p70S6K (p-pS6K). The p85S6K isoform is
also shown (3A). RPS6 and phosphorylated RPS6 (p-RPS6) levels were also determined by Western blot in these cell lines after serum starvation
using specific antibodies (3B). Erk 1/2 and phosphorylated Erk1/2 (p-Erk 1/2) levels were also determined in these cell lines after serum starvation
by Western blot (3C). HGUE-C-1, HT-29, SW620, SW480 and HCT-15 cells were grown, lysed and subjected to Western blot analyses using antibodies
against EGFR and HER3 (3D).
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termined by daunomycin uptake assays by flow cytometry
(data not shown).
Discussion
Herein we have characterized a new colon carcinoma
cell line, HGUE-C-1, obtained from the ascitic fluid from
a 76 years old patient with colon cancer. HGUE-C-1 cells
represent an interesting model of study from different
points of view. First, this cell line has been obtained from
a tumour that belongs to a group of colon carcinomas
lacking MSI, with loss of heterozygosity affecting the APC
locus, and without TP53, KRAS, BRAF or PIK3CA muta-
tions. These molecular characteristics are representative
of less than 12% of all colon carcinomas [20]. Second, an
extensive pharmacological profile of this cell line indicates
that it represents a physiological model of chemoresis-
tance (developed inside the patient) to 5-FU and irinote-
can, drugs that have been used to treat this patient. Third,
HGUE-C-1 cells show partial or total cross-resistance to
drugs never used in the patient before, such as cetuximab,
17-AAG, oxaliplatin or AZD-6244. Finally, HGUE-C-1
cells are still sensitive to other drugs such as TSA, rapa-
mycin, BEZ-235, sorafenib, erlotinib, gefitinib and others,
suggesting that different pathways can still be targeted in
patients with similar pharmacological profile and genetic
background than the patient from which HGUE-C-1 cells
were obtained.
As mentioned above, HGUE-C-1 cells are quite atyp-
ical when compared with other colon carcinoma cell
lines, or when we analyse the usual genetic changes re-
ported in colon carcinoma patients. In this sense, it isknown that around 10-15% of colon carcinomas have
MSI phenotype [21] and 50-55% of tumours carry muta-
tions in TP53 [22]. Similar percentages of mutations
(40-50%) are found in KRAS and BRAF [23] and 17% of
PIK3CA mutations have been determined in colon car-
cinoma patients [23,24]. This suggests that the probabil-
ity that a patient will not carry at least one of the above
mentioned genetic changes is quite low. For this reason,
HGUE-C-1 cells constitute an interesting and unique
cellular model of colorectal carcinoma.
Since HGUE-C-1 cells were not obtained from the pri-
mary tumour when it was resected two years earlier, it
becomes difficult to determine the initial events in car-
cinogenesis in this cellular model. Besides the loss of
heterozygosity affecting the APC locus that we have
found in HGUE-C-1 cells, we have studied different sig-
nal transduction pathways looking for modifications that
we could associate with HGUE-C-1 tumourigenesis and,
we have compared these results with the findings obtained
in HT-29 colon cancer cells, since this cell line constitutes
a paradigm of the colon carcinogenesis pathway proposed
by Vogelstein et al. [25]. HT-29 cells harbour APC, BRAF,
TP53 and PIK3CA mutations and MSI stability. HGUE-C-
1 cells expressed very low levels of Rb protein compared
with HT-29 cells. These low levels of protein expres-
sion correlate with low activity of Rb protein and with
increased activity of E2F, as demonstrated by transient
transfection of both cell lines with the appropriate reporter
genes (Figure 2). Our analysis also shows that HGUE-C-1
cells overexpress p70S6K (RPS6KB1), which correlates
with an increased activity of this kinase, as demonstrated
by its high level of phosphorylation under serum starved
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substrate RPS6 appears phosphorylated. Analysis of other
signalling molecules that belong to the Ras/Raf/Mek/Erk
and PI3K/Akt/mTOR pathways also shows some differ-
ences between both cell lines. Interestingly, Erk1 and Erk2
appear constitutively activated under serum starved condi-
tions in HGUE-C-1 cells, as demonstrated by the high
levels of Erk 1/2 phosphorylation. In addition, no expres-
sion of HER3 was observed in HGUE-C-1 cells. The re-
sults obtained open the possibility of a putative role of
RPS6KB1 or Erk 1/2 as second hits in HGUE-C-1 carcino-
genesis. Interestingly, several publications suggest that
RPS6KB1 may be involved in carcinogenesis. Ehrbrecht
et al. [26] have analyzed 22 sporadic desmoplastic medul-
loblastomas by comparative genomic hybridization (CGH),
finding in some of them an amplicon in chromosome 17
(17q22-24) where RPS6KB1 lies. Furthermore, they found
significantly elevated transcript levels of RPS6KB1 as com-
pared to normal cerebellum in 5 out of 6 desmoplasticmedulloblastomas and in 4 out of 5 classic medulloblasto-
mas analysed. The 17q23 amplicon has also been described
by Sinclair et al. [27] in breast cancer and they even have
suggested that RPS6KB1, TBX2 and PPM1D genes in-
cluded in this amplicon may act as oncogenes. Genetic
variation in RPS6KA1, RPS6KA2, RPS6KB1 and RPS6KB2
has been related to colon and rectal carcinoma in a recent
article by Slattery et al. [28].
On the other hand, RPS6KB1 is regulated by growth
factors such as EGF, PDGF and insulin, and is also regu-
lated by mTOR [29], suggesting that it can be involved
in cell growth regulation. In this sense, Sunayama et al.
[30] have shown that inhibition of the PI3K/mTOR and
the MEK/ERK pathways in glioblastoma stem-like cells in-
duces an increase in the activity of the other pathways and
that this cross-regulation disappeared when RPS6KB1 ex-
pression was inhibited by siRNAs. Using microarrays ana-
lysis, Chakraborty et al. [31] identified genes related to
tumourigenesis of retinoblastoma. Their results suggested
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PI3K/Akt/mTOR pathway. To corroborate this hypoth-
esis, the authors reported an increase in the expression
levels of PIK3CA, Akt, mTOR and RPS6KB1 in retino-
blastoma samples, when compared with normal tissue.
Taken together, these data suggested that loss of APC
function and over-expression of RPS6KB1 in HGUE-C-1
cells alone or in combination with low activity and expres-
sion of Rb protein, may constitute a driving force in the
HGUE-C-1 tumourigenesis.
HGUE-C-1 cells constitute a quite interesting model
from a pharmacological point of view since they can be
used for the study of intrinsic chemoresistance to 5-FU
and irinotecan, as shown in Figure 3. Since chemoresis-
tance was naturally acquired by the patient after treatment
with these chemotherapeutic agents, these cells represent
a more physiological model than the usual chemoresis-
tance cellular models obtained in the laboratory by se-
lective pressure of parental sensitive cells treated withincreasing concentrations of a particular drug. In addition,
clonal populations of HGUE-C-1 cells show different
degrees of resistance to 5-FU. We need to investigate
whether they represent different stages of a unique mo-
lecular mechanism of resistance or else, an alternative mo-
lecular mechanism of resistance developed inside the
patient. Other possibility is that due to tumour heterogen-
eity, clonal populations behave differently under the same
conditions.
HGUE-C-1 cells were also treated in culture with cetux-
imab, an antibody against the extracellular domain of
EGFR, since as mentioned above, this is a treatment used
in advanced colon carcinoma patients and since HGUE-
C-1 cells are wild type for KRAS and BRAF. As seen in
Figure 5A, HGUE-C-1 cells show resistance to cetuximab
despite the patient was not treated with this antibody.
Interestingly, HGUE-C-1 cells show sensitivity to erlotinib
and gefitinib, small organic molecules that inhibit the
tyrosine kinase activity of the EGFR. This is an unexpected
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the same target (EGFR). Mutations on exons 19 and 21
of EGFR have been related to tyrosine kinase inhibi-
tor activity [32]. Since EGFR is expressed in HGUE-C-1
cells (Figure 3E), our results suggest that probably erloti-
nib and gefitinib act in HGUE-C-1 cells through the in-
hibition of a secondary target other than EGFR. Evidences
showing inhibition of other tyrosine kinases by erlotinib
and gefitinib have been previously published [33].
In addition, the effect of several drugs affecting differ-
ent signal transduction pathways have been analysed on
HGUE-C-1 cells. Our results indicate that HGUE-C-1 cells
show similar degree of sensitivity to rapamycin, NVP-
BEZ235, sorafenib and TSA than HT-29 cells. These re-
sults indicate that inhibitors of the PI3K/mTOR pathway
may be a therapeutic alternative for colon carcinoma pa-
tients with resistance to 5-FU, irinotecan, oxaliplatin
and cetuximab. HGUE-C-1 cells are also sensitive to TSA
(Figure 6D) and SAHA (data not shown), indicating that
epigenetic treatments may be also a therapeutical alterna-
tive for these patients.HGUE-C-1 cell proliferation was also inhibited by soraf-
enib. We can postulate that the effects of sorafenib could
be due to the inhibition of BRAF, since HGUE-C-1 cells
show wild type BRAF. However, we cannot conclude that
this is the case since sorafenib also induces inhibition of
HT-29 cell proliferation, and this cell line harbours a mu-
tation in BRAF (V600E) [34]. We postulate that probably,
the inhibitory effect of sorafenib is mostly due to its cap-
acity to inhibit other tyrosine kinases [35,36], as it occurs
with erlotinib and gefitinib.
The Hsp90 inhibitor 17-AAG is able to inhibit HGUE-
C-1 cell proliferation, however, significant higher doses
of 17-AAG are needed to inhibit HGUE-C-1 cells than
HT-29 cells (Figure 7A). This partial response to 17-AAG
may be related to the resistance of HGUE-C-1 cells to
cetuximab. In this sense, it is believed that Hsp90 inhibi-
tors affect cell proliferation because they interfere in the
relationship between Hsp90 and their clients [37]. Some
of these clients are members of the HER family receptors
[38]. The lack of cetuximab effect may indicate that EGFR
does not play a significant role in HGUE-C-1 cells and,
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could be no significantly important for HGUE-C-1 cell
proliferation.
HGUE-C-1 cells also show resistance to AZD-6244
(selumetinib), a Mek inhibitor (Figure 7B). The molecular
mechanisms involved in this resistance remain unknown.
However, a putative explanation arises analysing the ef-
fects of the different drugs on cell cycle distribution, asseen in Figure 8. When we compare the effects of sorafe-
nib, NVP-BEZ235, 17-AAG, AZD-6244 and TSA, we ob-
served that in the case of HT-29 cells, the different drugs
induce a partial blockade in different phases of the cell
cycle and later, some percentage of the cells undergo
apoptosis, as determined by an increase in the subG1
population. However, this is quite different in HGUE-C-1
cells, since in this cell line, all drugs that affect cell
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phase, without previous accumulation in any of the phases
of the cell cycle. Even in the case of AZD-6244 treatment,
where a very low and no significant effect on cell prolifera-
tion was observed, we could detect a small increase in the
subG1 cell population without any sign of cell accumula-
tion in G1, as opposed to the results obtained in HT-29
cells. Taking together, our data suggest that defects on the
G1/S checkpoint boundary in HGUE-C-1 cells due mainly
to the low expression and activity of Rb, together with the
increase on E2F activity (Figure 2C), are directly related to
the lack of effect of AZD-6244 and to the partial effect of
17-AAG treatments in HGUE-C-1 cells.
Finally, HGUE-C-1 cells show resistance to oxaliplatin
despite the patient was not treated with this compound.
This resistance is important because as mentioned in the
introduction, this compound increases survival in advanced
colon carcinoma patients when added to the standard
therapy with 5-FU or capecitabine and irinotecan [5-7].
The molecular mechanisms responsible for oxaliplatinresistance in HGUE-C-1 cells remain unknown. However,
we believe that the low levels of Rb protein and activity
may be involved in such mechanisms. Oxaliplatin dam-
ages the DNA inducing double strand breaks [39]. Since
HGUE-C-1 cells do not show MSI and express wild type
TP53, the expected response to oxaliplatin treatment in
HGUE-C-1 cells should be p53 stabilization. Then, p53
will increase p21 and other proteins that will block the cell
cycle in the G1 phase. Since as we have shown the G1/S
checkpoint is seriously compromised by the low activity of
Rb with the concomitant increase in E2F activity, HGUE-
C-1 cells will be able to proliferate in such conditions. On
the other hand, p53 will also increase the transcription of
proapoptotic proteins such as NOXA and PUMA [40] but
again, HGUE-C-1 cells are able to survive in this condi-
tions probably because as mentioned before, loss of Rb or
decrease in its activity have been related to deregulation of
PI3K/Akt/mTOR signal transduction pathway [41]. This
pathway has been extensively related with cell survival for
example inhibiting the proapototic protein BAD [42]. In
Grasso et al. BMC Cancer  (2015) 15:240 Page 15 of 16this sense, it is interesting to mention that p70S6K that is
constitutively active in HGUE-C-1 is able to phosphoryl-
ate BAD [43].
Conclusions
HGUE-C-1 is a new colon carcinoma cell line with inter-
esting characteristics. First, it constitutes an example of a
small percentage of colon carcinomas without MSI, with
compromised APC activity but without TP53, KRAS,
BRAF or PIK3CA mutations. Comparative analysis of dif-
ferent signal transduction pathways in HGUE-C-1 versus
HT-29 colon carcinoma cell lines show that lack of APC
activity, low expression and activity of Rb protein together
with an over-expression and high activation of p70S6K
and constitutive activation of Erk1/2, may be the driving
force of HGUE-C-1 carcinogenesis. HGUE-C-1 cells also
constitute an interesting cellular model to study che-
moresistance acquisition to 5-FU, irinotecan, oxaliplatin,
17-AAG and AZD-6244. Interestingly, resistance to some
of these drugs was acquired inside the patient as a conse-
quence of the chemotherapeutical treatment (5-FU and
irinotecan), being the partial or total resistance to 17-
AAG, oxaliplatin and AZD-6244 unrelated to patients
treatment. The molecular mechanisms regulating resist-
ance to these compounds remain unknown. However,
strong evidences suggest that the incapacity of HGUE-C-1
cells to be blocked in the G1/S cell cycle checkpoint can
be the consequence of low Rb activity and the subsequent
high E2F activity.
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